- Home
- ACIC vs CBIO Comparison
ACIC vs CBIO Comparison
Compare ACIC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ACIC | CBIO |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 537.5M |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ACIC | CBIO |
|---|---|---|
| Price | $9.26 | $16.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | ★ 271.6K | 213.6K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $335,439,000.00 | $18,500.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | $279.20 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.33 | $8.72 |
| 52 Week High | $13.06 | $27.41 |
Technical Indicators
Market Signals| Indicator | ACIC | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.09 | 47.79 |
| Support Level | N/A | $14.46 |
| Resistance Level | $11.48 | $16.35 |
| Average True Range (ATR) | 0.39 | 1.05 |
| MACD | -0.10 | 0.10 |
| Stochastic Oscillator | 2.23 | 54.19 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.